104 results match your criteria targeting bnp


Date Palm Pollen Extract Avert Doxorubicin-Induced Cardiomyopathy Fibrosis and Associated Oxidative/Nitrosative Stress, Inflammatory Cascade, and Apoptosis-Targeting Bax/Bcl-2 and Caspase-3 Signaling Pathways.

Animals (Basel) 2021 Mar 20;11(3). Epub 2021 Mar 20.

Department of Physiology, Faculty of Veterinary Medicine, Kafrelsheikh University, Kafrelsheikh 33516, Egypt.

Doxorubicin (DOX) has a potent antineoplastic efficacy and is considered a cornerstone of chemotherapy. However, it causes several dose-dependent cardiotoxic results, which has substantially restricted its clinical application. This study was intended to explore the potential ameliorative effect of date palm pollen ethanolic extract (DPPE) against DOX-induced cardiotoxicity and the mechanisms underlying it. Read More

View Article and Full-Text PDF

Circular RNA POSTN Promotes Myocardial Infarction-Induced Myocardial Injury and Cardiac Remodeling by Regulating miR-96-5p/BNIP3 Axis.

Front Cell Dev Biol 2020 18;8:618574. Epub 2021 Feb 18.

Department of Cardiovascular Surgery, PLA General Hospital, Beijing, China.

Myocardial infarction (MI) is the most prevalent cardiac disease with high mortality, leading to severe heart injury. Circular RNAs (circRNAs) are a new type of regulatory RNAs and participate in multiple pathological cardiac progressions. However, the role of circRNAs Postn (circPostn) in MI modulation remains unclear. Read More

View Article and Full-Text PDF
February 2021

An ultrasensitive heart-failure BNP biosensor using B/N co-doped graphene oxide gel FET.

Biosens Bioelectron 2021 May 26;180:113114. Epub 2021 Feb 26.

Mechanical and Mechatronics Engineering, University of Waterloo, Waterloo, ON, Canada; Waterloo Institute for Nanotechnology (WIN), University of Waterloo, Waterloo, ON, Canada.

Heart failure (HF) is the number one cause of death in the world. B-type natriuretic peptide (BNP) is a recognized biomarker for HF and can be used for early detection. Field effect transistor (FET) biosensors have the ability to sense BNP in much shorter times than conventional clinical studies. Read More

View Article and Full-Text PDF

PHD Finger Protein 19 Promotes Cardiac Hypertrophy via Epigenetically Regulating SIRT2.

Cardiovasc Toxicol 2021 Jun 21;21(6):451-461. Epub 2021 Feb 21.

Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University and Beijing Institute of Heart Lung and Blood Vessel Diseases, 2 Anzhen Road, Beijing, China.

Epigenetic regulations essentially participate in the development of cardiomyocyte hypertrophy. PHD finger protein 19 (PHF19) is a polycomb protein that controls H3K36me3 and H3K27me3. However, the roles of PHF19 in cardiac hypertrophy remain unknown. Read More

View Article and Full-Text PDF

MicroRNA-30a-5p silencing polarizes macrophages toward M2 phenotype to alleviate cardiac injury following viral myocarditis by targeting SOCS1.

Am J Physiol Heart Circ Physiol 2021 04 8;320(4):H1348-H1360. Epub 2021 Jan 8.

Department of Cardiology, the First People's Hospital of Yunnan Province, Affiliated Hospital of Kunming University of Science and Technology, Kunming, People's Republic of China.

Viral myocarditis (VMC) is a life-threatening disease characterized by severe cardiac inflammation generally caused by coxsackievirus B3 (CVB3) infection. Several microRNAs (miRNAs or miRs) are known to play crucial roles in the pathogenesis of VMC. The study aimed to decipher the role of miR-30a-5p in the underlying mechanisms of VMC pathogenesis. Read More

View Article and Full-Text PDF

Differential Role of Circulating microRNAs to Track Progression and Pre-Symptomatic Stage of Chronic Heart Failure: A Pilot Study.

Biomedicines 2020 Dec 11;8(12). Epub 2020 Dec 11.

Immunology and Functional Genomics Unit, Centro Cardiologico Monzino-IRCCS, 20138 Milan, Italy.

(1)Background: Chronic heart failure (CHF) contributes to the overall burden of cardiovascular disease. Early identification of at-risk individuals may facilitate the targeting of precision therapies. Plasma microRNAs are promising circulating biomarkers for their implications with cardiac pathologies. Read More

View Article and Full-Text PDF
December 2020

Mep1a contributes to Ang II-induced cardiac remodeling by promoting cardiac hypertrophy, fibrosis and inflammation.

J Mol Cell Cardiol 2021 03 8;152:52-68. Epub 2020 Dec 8.

State Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Institute of Basic Medical Sciences, Department of Pathophysiology, Peking Union Medical College, Beijing, China. Electronic address:

Pathological cardiac remodeling, characterized by excessive deposition of extracellular matrix proteins and cardiac hypertrophy, leads to the development of heart failure. Meprin α (Mep1a), a zinc metalloprotease, previously reported to participate in the regulation of inflammatory response and fibrosis, may also contribute to cardiac remodeling, although whether and how it participates in this process remains unknown. Here, in this work, we investigated the role of Mep1a in pathological cardiac remodeling, as well as the effects of the Mep1a inhibitor actinonin on cardiac remodeling-associated phenotypes. Read More

View Article and Full-Text PDF

The cardiovascular determinants of physical function in patients with end-stage kidney disease on haemodialysis.

Int J Cardiovasc Imaging 2021 Apr 30;37(4):1405-1414. Epub 2020 Nov 30.

Department of Cardiovascular Sciences, University of Leicester and NIHR Leicester Cardiovascular Biomedical Research Centre, Glenfield Hospital, Leicester, UK.

Patients with end-stage kidney disease (ESKD) are often sedentary and decreased functional capacity associates with mortality. The relationship between cardiovascular disease (CVD) and physical function has not been fully explored. Understanding the relationships between prognostically relevant measures of CVD and physical function may offer insight into how exercise interventions might target specific elements of CVD. Read More

View Article and Full-Text PDF

miR-133a-3p attenuates cardiomyocyte hypertrophy through inhibiting pyroptosis activation by targeting IKKε.

Acta Histochem 2021 Jan 24;123(1):151653. Epub 2020 Nov 24.

Department of Cardiovascular Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, People's Republic of China. Electronic address:

Objective: Cardiac hypertrophy is an adaptive response to physiological and pathological stimuli, the latter of which frequently progresses to valvulopathy, heart failure and sudden death. Recent reports revealed that pyroptosis is involved in regulating multiple cardiovascular diseases progression, including cardiac hypertrophy. However, the underlying mechanisms remain poorly understood. Read More

View Article and Full-Text PDF
January 2021

Atrial nitroso-redox balance and refractoriness following on-pump cardiac surgery: A randomised trial of atorvastatin.

Cardiovasc Res 2020 Oct 24. Epub 2020 Oct 24.

Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.

Aims: Systemic inflammation and increased activity of atrial NOX2-containing NADPH oxidases have been associated with the new onset of atrial fibrillation (AF) after cardiac surgery. In addition to lowering LDL-cholesterol, statins exert rapid anti-inflammatory and antioxidant effects, the clinical significance of which remains controversial.

Methods And Results: We first assessed the impact of cardiac surgery and cardiopulmonary bypass (CPB) on atrial nitroso-redox balance by measuring NO synthase (NOS) and GTP Cyclohydrolase -1 (GCH-1) activity, biopterin content, and superoxide production in paired samples of the right atrial appendage obtained before (PRE) and after CPB and reperfusion (POST) in 116 patients. Read More

View Article and Full-Text PDF
October 2020

The chromogranin A fragment reveals how a single change in the protein sequence exerts strong cardioregulatory effects by engaging neuropilin-1.

Acta Physiol (Oxf) 2021 04 1;231(4):e13570. Epub 2020 Nov 1.

Laboratory of Cellular and Molecular Cardiovascular Patho-Physiology, Department of Biology, E. and E.S., University of Calabria, Rende, Italy.

Aim: Chromogranin A (CgA), a 439-residue long protein, is an important cardiovascular regulator and a precursor of various bioactive fragments. Under stressful/pathological conditions, CgA cleavage generates the CgA proangiogenic fragment. The present work investigated the possibility that human CgA influences the mammalian cardiac performance, evaluating the role of its C-terminal sequence. Read More

View Article and Full-Text PDF

Daratumumab Monotherapy in Severe Patients with AL Amyloidosis and Biopsy-Proven Renal Involvement: A Real Life Experience.

J Clin Med 2020 Oct 9;9(10). Epub 2020 Oct 9.

CMID-Nephrology and Dialysis Unit (ERK-net Member)-Center of Research of Nephrology, Rheumatology, and Rare Diseases, Interregional Coordinating Center of the Network of Rare Diseases, G. Bosco Hospital and University of Turin, 10152 Turin, Italy.

Objectives: This paper aims to describe the clinical experience with Daratumumab (DARA), a first-in-class anti-CD38 human monoclonal IgG1κ antibody monotherapy, in severe patients with AL and biopsy-proven renal involvement. Immunoglobulin light chain (AL) amyloidosis with multi-organ involvement is characterized by short survival. Novel powerful drugs are expanding the therapeutic options. Read More

View Article and Full-Text PDF
October 2020

Assessment of causality of natriuretic peptides and atrial fibrillation and heart failure: a Mendelian randomization study in the FINRISK cohort.

Europace 2020 10;22(10):1463-1469

Department of General and Interventional Cardiology, University Heart Centre Hamburg, Martinistr. 52, 20246 Hamburg, Germany.

Aims: Natriuretic peptides are extensively studied biomarkers for atrial fibrillation (AF) and heart failure (HF). Their role in the pathogenesis of both diseases is not entirely understood and previous studies several single-nucleotide polymorphisms (SNPs) at the NPPA-NPPB locus associated with natriuretic peptides have been identified. We investigated the causal relationship between natriuretic peptides and AF as well as HF using a Mendelian randomization approach. Read More

View Article and Full-Text PDF
October 2020

Pyrroloquinoline quinone can prevent chronic heart failure by regulating mitochondrial function.

Cardiovasc Diagn Ther 2020 Jun;10(3):453-469

Department of Cardiology, Affiliated Hospital of Nantong University, Nantong, China.

Background: Myocardial mitochondrial dysfunction is the leading cause of chronic heart failure (CHF). Increased reactive oxygen species (ROS) levels, disruption of mitochondrial biogenesis and mitochondrial Ca([Ca]m) homeostasis and reduction of the mitochondrial membrane potential (ΔΨm) cause myocardial mitochondrial dysfunction. Therefore, treating CHF by targeting mitochondrial function is a focus of current research. Read More

View Article and Full-Text PDF

Time to Redefine Risk-Stratification and Response Criteria in Immunoglobulin Light Chain Amyloidosis?

Clin Lymphoma Myeloma Leuk 2020 10 7;20(10):e769-e776. Epub 2020 Jun 7.

Department of Haematology, Oxford University Hospitals, NHS Foundation Trust; NIHR BRC Blood Theme, Oxford, England, UK; Oxford Myeloma Centre for Translational Research.

Immunoglobulin light chain (AL) amyloidosis results from clonal plasma cell (PC)-derived immunoglobulin light chain-mediated end-organ dysfunction, the extent and severity of which predicts survival. Anti-PC therapies reduce clonal light chain burden, which usually results in improvement of organ function, and consequently overall survival. Response assessment is critical to gauge therapeutic efficacy, to report clinical trial outcomes, and to switch therapy in those without response. Read More

View Article and Full-Text PDF
October 2020

Up-regulation of miR-195 contributes to cardiac hypertrophy-induced arrhythmia by targeting calcium and potassium channels.

J Cell Mol Med 2020 07 28;24(14):7991-8005. Epub 2020 May 28.

Department of Pharmacology, Harbin Medical University (the State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang, China.

Previous studies have confirmed that miR-195 expression is increased in cardiac hypertrophy, and the bioinformatics website predicted by Targetscan software shows that miR-195 can directly target CACNB1, KCNJ2 and KCND3 to regulate Cavβ1, Kir2.1 and Kv4.3 proteins expression. Read More

View Article and Full-Text PDF

Design and in vitro characterization of multistage silicon-PLGA budesonide particles for inflammatory bowel disease.

Eur J Pharm Biopharm 2020 Jun 10;151:61-72. Epub 2020 Apr 10.

Department of Nanomedicine, Houston Methodist Research Institute, Houston, TX, USA. Electronic address:

Inflammatory bowel disease (IBD) affects a confined area of the intestine and, therefore, administration of drugs via oral route is preferable. However, obstacles such as changes in the pH along gastrointestinal tract (GIT), enzymatic activity, and intraluminal pressure may cause low drug availability in the target tissue when delivered orally. Previous studies have pointed out the benefits of using micron-sized particles for targeting inflamed intestinal mucosa and nanoparticles for delivery of anti-inflammatory agents to the affected epithelial cells. Read More

View Article and Full-Text PDF

MicroRNA-208-5p regulates myocardial injury of sepsis mice via targeting SOCS2-mediated NF-κB/HIF-1α pathway.

Int Immunopharmacol 2020 Apr 18;81:106204. Epub 2020 Feb 18.

Department of Cardiology, Shunde Hospital, Southern Medical University (The First People's Hospital of Shunde Foshan), Foshan 528300, Guangdong, China. Electronic address:

Background: Accumulating evidence has revealed the roles of microRNAs (miRs) in sepsis, hence, the aim of the present study was to investigate whether miR-208a-5p affects sepsis whilst attempting to elucidate the mechanisms by which the suppressors of cytokine signaling 2 (SOCS2)-mediated nuclear factor-kappaB/hypoxia-inducible factor-1α (NF-κB/HIF-1α) pathway is implicated in this process.

Methods: The sepsis model was established by cecal ligation and puncture in mice. Serum levels of myocardial enzyme cardiac Troponin-I (cTnI) and brain natriuretic peptide (BNP) in mice were measured. Read More

View Article and Full-Text PDF

Activation of the Nitric Oxide Pathway and Acute Myocardial Infarction Complicated by Acute Kidney Injury.

Cardiorenal Med 2020 20;10(2):85-96. Epub 2020 Jan 20.

Université Paris Diderot, PRES Sorbonne Paris Cité, Paris, France.

Background/aims: The pathophysiology of acute kidney injury (AKI) in ST-elevation myocardial infarction (STEMI) patients remains poorly explored. The involvement of the nitric oxide (NO) pathway has been demonstrated in experimental ischemic AKI. The aim of this study was to assess the predictive value of circulating biomarkers of the NO pathway for AKI in STEMI patients. Read More

View Article and Full-Text PDF
January 2020

Targeting Natriuretic Peptide Levels in Heart Failure with Therapy: Does "X" Really Mark the Spot?

Curr Heart Fail Rep 2019 12;16(6):250-256

Department of Medicine, Duke University School of Medicine, Durham, NC, USA.

Purpose Of Review: Explore controversial biomarker-guided management of patients with heart failure (HF) with reduced ejection fraction.

Recent Findings: Natriuretic peptides (e.g. Read More

View Article and Full-Text PDF
December 2019

Treatment of Pulmonary Hypertension With Angiotensin II Receptor Blocker and Neprilysin Inhibitor Sacubitril/Valsartan.

Circ Heart Fail 2019 11 11;12(11):e005819. Epub 2019 Nov 11.

Vascular Research Laboratory, Providence VA Medical Center, RI (R.T.C., A.V.A.B., A.F.-N., N.R.K., T.J.M., A.R.M., K.M., G.C.).

Background: Angiotensin II has been implicated in maladaptive right ventricular (RV) hypertrophy and fibrosis associated with pulmonary hypertension (PH). Natriuretic peptides decrease RV afterload by promoting pulmonary vasodilation and inhibiting vascular remodeling but are degraded by neprilysin. We hypothesized that angiotensin receptor blocker and neprilysin inhibitor, sacubitril/valsartan (Sac/Val, LCZ696), will attenuate PH and improve RV function by targeting both pulmonary vascular and RV remodeling. Read More

View Article and Full-Text PDF
November 2019

Expression of microRNA-514a-5p and its biological function in experimental pulmonary thromboembolism.

Am J Transl Res 2019 15;11(9):5514-5530. Epub 2019 Sep 15.

Department of Respiratory Medicine, Shandong Provincial Hospital Affiliated to Shandong University Jinan 250000, Shandong, China.

It is difficult to diagnose pulmonary thromboembolism (PTE) in clinical practice. While microRNAs (miRNAs) have been widely investigated as biomarkers for various diseases, their value as biomarkers for PTE remains largely unknown. In the present study, 83 miRNAs showed altered expression in an intermediate-risk PTE group when compared with their expression in a low-risk PTE group as detected by miRNA microarray analysis. Read More

View Article and Full-Text PDF
September 2019

Dynamic Changes in the Molecular Signature of Adverse Left Ventricular Remodeling in Patients With Compensated and Decompensated Chronic Primary Mitral Regurgitation.

Circ Heart Fail 2019 09 12;12(9):e005974. Epub 2019 Sep 12.

Division of Cardiology, Department of Internal Medicine (K.M., S.G., L.M., N.T., A.V., D.Z., P.M.), Charlotte Maxeke Johannesburg Academic Hospital & University of the Witwatersrand, Johannesburg, South Africa.

Background: There is no proven medical therapy that attenuates adverse left ventricular remodeling in patients with chronic primary mitral regurgitation (CPMR). Identification of molecular pathways important in the progression of left ventricular remodeling in patients with CPMR may lead to development of new therapeutic strategies.

Methods And Results: We performed baseline echocardiographic, cardiac catheterization, and serum NT-pro-BNP analysis in patients with severe CPMR awaiting mitral valve surgery and stratified the study population into compensated or decompensated CPMR. Read More

View Article and Full-Text PDF
September 2019

Targeting GATA4 for cardiac repair.

IUBMB Life 2020 01 16;72(1):68-79. Epub 2019 Aug 16.

Drug Research Program, Division of Pharmacology and Pharmacotherapy, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.

Various strategies have been applied to replace the loss of cardiomyocytes in order to restore reduced cardiac function and prevent the progression of heart disease. Intensive research efforts in the field of cellular reprogramming and cell transplantation may eventually lead to efficient in vivo applications for the treatment of cardiac injuries, representing a novel treatment strategy for regenerative medicine. Modulation of cardiac transcription factor (TF) networks by chemical entities represents another viable option for therapeutic interventions. Read More

View Article and Full-Text PDF
January 2020

Long noncoding RNA MAGI1-IT1 regulates cardiac hypertrophy by modulating miR-302e/DKK1/Wnt/beta-catenin signaling pathway.

J Cell Physiol 2020 01 21;235(1):245-253. Epub 2019 Jun 21.

Department of Cardiovascular Surgery, the 2nd Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.

Cardiac hypertrophy (CH) is an adaptive cardiac response to overload whose decompensation eventually leads to heart failure or sudden death. Recently, accumulating studies have indicated the implication of long noncoding RNAs (lncRNAs) in CH progression. MAGI1-IT1 is a newly-identified lncRNA that is highly associated with CH, while its specific role in CH progression remains masked. Read More

View Article and Full-Text PDF
January 2020

A Post hoc analysis on rhythm and high intensity interval training in cardiac resynchronization therapy.

Scand Cardiovasc J 2019 Aug 21;53(4):197-205. Epub 2019 Jun 21.

a Faculdade de Motricidade Humana , Universidade de Lisboa, CIPER - Centro Interdisciplinar de Estudo da Performance Humana, Portugal , Lisboa , Portugal.

. Evaluate the effects of a 6-month High Intensity Interval Training (HIIT) program on (1) functional capacity and health-related quality of life, (2) multiple blood biomarkers, (3) echocardiographic parameters, and (4) exercise performance, in patients in cardiac resynchronization therapy (CRT) stratified by the presence of atrial fibrillation (AF), targeting the following questions: (1) Does CRT provide similar benefits in patients in AF and sinus rhythm (SR)?; and (2) Does HIIT provides similar benefits in patients in AF and SR? Estimates were available at baseline and 6 months after CRT implantation in 37 patients with heart failure. Patients were randomized after CRT to a 24-week HIIT group or to a usual care group (CON). Read More

View Article and Full-Text PDF

Myocarditis in Cynomolgus Monkeys Following Treatment with Immune Checkpoint Inhibitors.

Clin Cancer Res 2019 08 13;25(15):4735-4748. Epub 2019 May 13.

Global Pathology, DSRD, Pfizer, La Jolla, California.

Purpose: Immune checkpoint inhibitors (ICI) targeting PD1, PDL1, or CTLA4 are associated with immune-related adverse events (irAE) in multiple organ systems including myocarditis. The pathogenesis and early diagnostic markers for ICI-induced myocarditis are poorly understood, and there is currently a lack of laboratory animal model to enhance our understanding. We aimed to develop such a model using cynomolgus monkeys. Read More

View Article and Full-Text PDF

C-type Natriuretic Peptide: A Multifaceted Paracrine Regulator in the Heart and Vasculature.

Int J Mol Sci 2019 May 8;20(9). Epub 2019 May 8.

William Harvey Research Institute, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK.

C-type natriuretic peptide (CNP) is an autocrine and paracrine mediator released by endothelial cells, cardiomyocytes and fibroblasts that regulates vital physiological functions in the cardiovascular system. These roles are conveyed via two cognate receptors, natriuretic peptide receptor B (NPR-B) and natriuretic peptide receptor C (NPR-C), which activate different signalling pathways that mediate complementary yet distinct cellular responses. Traditionally, CNP has been deemed the endothelial component of the natriuretic peptide system, while its sibling peptides, atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP), are considered the endocrine guardians of cardiac function and blood volume. Read More

View Article and Full-Text PDF

Distinct contribution of Rac1 expression in cardiomyocytes to anthracycline-induced cardiac injury.

Biochem Pharmacol 2019 06 29;164:82-93. Epub 2019 Mar 29.

Institute of Toxicology, Medical Faculty, Heinrich-Heine University Düsseldorf, Moorenstrasse 5, D-40225 Düsseldorf, Germany. Electronic address:

Cardiotoxicity is the dose limiting adverse effect of anthracycline-based anticancer therapy. Inhibitor studies point to Rac1 as therapeutic target to prevent anthracycline-induced cardiotoxicity. Yet, supporting genetic evidence is still missing and the pathophysiological relevance of different cardiac cell types is unclear. Read More

View Article and Full-Text PDF

Design, Synthesis, and Actions of an Innovative Bispecific Designer Peptide.

Hypertension 2019 04;73(4):900-909

From the Cardiorenal Research Laboratory (L.M.G.M., I.A.A., S.P., G.H., Y.C., Y.Z., G.E.H., T.I., D.M.H., S.R.I., S.J.S., J.C.B.), Mayo Clinic, Rochester, MN.

Despite optimal current therapies, cardiovascular disease remains the leading cause for death worldwide. Importantly, advances in peptide engineering have accelerated the development of innovative therapeutics for diverse human disease states. Additionally, the advancement of bispecific therapeutics targeting >1 signaling pathway represents a highly innovative strategy for the treatment of cardiovascular disease. Read More

View Article and Full-Text PDF